Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol dose-response trial in moderate-to-severe chronic plaque psoriasis
2005-002141-39Phase 2Completed
- Sponsor
- UCB
- Start
- Sep 2005
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of certolizumab pegol in plaque psoriasis (3 arms), sponsored by UCB. Primary endpoints: PASI75 response at week 12 and PGA clear or almost clear at week 12. Started Sep 2005; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2005-002141-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002141-39.